Market Size of High Content Screening Industry
| Study Period | 2021 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 8.74 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
High Content Screening (HCS) Market Analysis
The High-content Screening Market is poised to grow at a CAGR of 8.74% over the forecast period.
The outbreak of COVID-19 has turned the spotlight on the high-content screening market as most biopharmaceutical players were engaged in the development of novel therapeutics against the SARS-CoV-2 virus. Due to the increase in drug discovery, there was an increasing demand for drug testing products and services to monitor and evaluate the toxicity of a specific vaccine before commercializing it to the market. Due to this, the pandemic had a positive impact on the high-content screening market. According to the research article published in the American Chemical Society Pharmacology and Translational Science in 2020, new potential therapeutics for COVID-19 identified with a combined virtual and experimental screening strategy and selected from among the already approved drugs were studied to screen for structural similarity against a library of almost 4000 approved drugs with hydroxychloroquine (HCQ) as a reference drug. The study proposed zuclopenthixol, nebivolol, and amodiaquine as potential candidates for clinical trials against the early phase of the SARS-CoV-2 infection and remdesivir and favipiravir therapeutics as potential adjuvants in COVID-19 treatment. With the rising use of high-content screening for such studies, COVID-19 significantly impacted the market studied. The market is expected to show stable growth during the forecast period.
The need for cost containment in pharmaceutical research and development, advancements in informatics solutions and imaging instruments, and government funding and venture capital investments across developed markets are the major factors driving the growth of the High-Content Screening (HCS) Market.
Under the conventional method of toxicity studies, large libraries are screened in search of potential drug candidates. The traditional way is expensive, resource- and time-consuming, and it has a low success rate. Consequent High-Content Screening (HCS) solutions for testing the potential toxicity of chemicals and complex substances are being adopted by pharmaceutical companies to improve in-vitro toxicity testing by reducing the time and cost. The increasing number of contract research organizations providing HCS outsourcing services and the application of HCS in personalized medicine present significant growth opportunities in the market.
The recent technological developments by the market players and researchers, rising investments, and rising research and development activities worldwide are contributing to the growth of the studied market. For instance, in October 2021, BD Life Sciences-Biosciences launched its second Center of Excellence (CoE) in flow cytometry for clinical research in India in collaboration with Christian Medical College, Vellore. The partnership will allow hematologists, doctors, and lab professionals from all over India to deliberate and discuss standardization and best practices in clinical flow cytometry. This CoE will function as the National Reference Center for clinical diagnostics applications and is estimated to propel the High-Content Screening Market during the forecast period.
Furthermore, in April 2022, CytoTronics received USD 9.25 million in initial seed funding led by Anzu Partners, with participation from Milad Alucozai (BoxOne Ventures) and institutional investors. This funding will allow the company to commercialize its research-demonstrated devices for cell-based drug screening in multiple areas, such as oncology, gastroenterology, cardiology, and neurology. It is likely to expand its offerings in terms of bringing technologically advanced products to the market for drug screening purposes which is expected to propel the High-Content Screening Market during the forecast period.
Hence, with the factors such as rising healthcare investment, and increasing strategic initiatives by key players, it is believed that the market studied will witness healthy growth over the forecast period.
